Vol.

No.

July 12, 2024Jul 12, 2024

DOWNLOAD THE PDF

NCI’s new chief data scientist Warren Kibbe tells us about efforts to get “AI-ready” “All research now involves data science at some level.”

Cover Story

Conversation with The Cancer Letter

NCI’s new chief data scientist Warren Kibbe tells us about efforts to get “AI-ready”

“All research now involves data science at some level.”

By Paul Goldberg

What can NCI accomplish in data science?

Conversation with The Cancer Letter

Infections are a major cause of death in patients treated with CAR T-cell therapy
Meta-analysis focused on causes of death, excluding relapse, recurrence

By Matthew Bin Han Ong

Cancer History Project

“If I’m not dying, I better go live.” Christy Erickson’s cancer diagnosis led to life as a motorcyclist and strongman competitor

By McKenzie Prillaman

Free In the Archives

Jänne, Ramalingam, Yu, Winn, Williams, Legg discuss today’s challenges in EGFR research at Yale SPORE workshop

In Brief

Lei Zheng named executive director of Mays Cancer Center

Mark Burkard named director of UI Health Care Holden Comprehensive Cancer Center

Glen Barber named director of Center for Innate Immunity and Inflammation at Ohio State’s Pelotonia Institute for Immuno-Oncology

Tiffany Seagroves joins Tulane Cancer Center

Linda Liau elected to Taiwan’s Academia Sinica

UCLA radiation oncologists awarded $1.8M to advance personalized cancer therapy

Sanaz Memarzadeh receives $4.1M to develop immune therapies for ovarian cancer

UAMS receives $1.3M for high school-focused tech and data science exposure program

Stephan Braun named chief medical officer of ImCheck

Clinical Roundup

Mayo Clinic performs world’s first known successful total larynx transplant in a patient with active cancer

Tiragolumab + atezolizumab for metastatic nSq NSCLC did not meet primary endpoints in phase II/III trial

Chemotherapy disrupts gut microbiome in patients with breast cancer

Survivorship standards help address the distinct needs of adult cancer survivors

Novel Co-STAR receptor shows promise treating cancers in preclinical study

Exscientia builds AWS AI-powered platform to advance drug discovery

Drugs & Targets

FDA grants Fast Track designation to 225Ac-FL-020 radiopharmaceutical for mCRPC

Boehringer Ingelheim, OSE Immunotherapeutics collaborate to advance clinical development of SIRP immuno-oncology program

Wistar, Accelerated Biosciences collaborate to develop immune cell therapies

PREVIOUS ISSUE

NEXT ISSUE

Recent Issues

NCI’s new chief data scientist Warren Kibbe tells us about efforts to get “AI-ready”

Infections are a major cause of death in patients treated with CAR T-cell therapy
Meta-analysis focused on causes of death, excluding relapse, recurrence

“If I’m not dying, I better go live.” Christy Erickson’s cancer diagnosis led to life as a motorcyclist and strongman competitor

Jänne, Ramalingam, Yu, Winn, Williams, Legg discuss today’s challenges in EGFR research at Yale SPORE workshop

In Brief

Lei Zheng named executive director of Mays Cancer Center

Mark Burkard named director of UI Health Care Holden Comprehensive Cancer Center

Glen Barber named director of Center for Innate Immunity and Inflammation at Ohio State’s Pelotonia Institute for Immuno-Oncology

Tiffany Seagroves joins Tulane Cancer Center

Linda Liau elected to Taiwan’s Academia Sinica

UCLA radiation oncologists awarded $1.8M to advance personalized cancer therapy

Sanaz Memarzadeh receives $4.1M to develop immune therapies for ovarian cancer

UAMS receives $1.3M for high school-focused tech and data science exposure program

Stephan Braun named chief medical officer of ImCheck

Clinical Roundup

Mayo Clinic performs world’s first known successful total larynx transplant in a patient with active cancer

Tiragolumab + atezolizumab for metastatic nSq NSCLC did not meet primary endpoints in phase II/III trial

Chemotherapy disrupts gut microbiome in patients with breast cancer

Survivorship standards help address the distinct needs of adult cancer survivors

Novel Co-STAR receptor shows promise treating cancers in preclinical study

Exscientia builds AWS AI-powered platform to advance drug discovery

Drugs & Targets

FDA grants Fast Track designation to 225Ac-FL-020 radiopharmaceutical for mCRPC

Boehringer Ingelheim, OSE Immunotherapeutics collaborate to advance clinical development of SIRP immuno-oncology program

Wistar, Accelerated Biosciences collaborate to develop immune cell therapies

Recent Issues

Renew today!

Subscriber content

Never miss an issue!

Login